Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

| More on:
Two lab workers fist pump each other.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

For those who've owned Sigma Healthcare Ltd (ASX: SIG) shares this year, it's been a joyful ride.

Shares in the ASX healthcare stock are up more than 148% this year to date on the back of the planned merger with Chemist Warehouse.

Sigma shares surged nearly 40% shortly after the Australian Competition and Consumer Commission (ACCC) approved the deal.

But with such a rally comes significant profits for those holding large stakes in the company.

According to ASX filings this week, HMC Capital Ltd (ASX: HMC) has completed a large sell-down in its Sigma position.

This raises the question of whether now is a prime opportunity to cash in. Let's take a closer look.

Why is HMC Capital offloading Sigma shares?

The Sigma–Chemist Warehouse deal was approved on 7 November after a lengthy review process that examined potential anti-competition impacts.

Completed via a backdoor listing, the deal saw the pair merge to create a healthcare giant that, according to the ACCC, was "unlikely to substantially lessen competition".

Sigma shares exploded higher on the news. And while plenty of investors were buying for the near-term gains, some shareholders were downsizing their positions.

HMC Capital immediately sold down its stake in Sigma, dropping its holdings from 10.64% to 8.24% on the same day as the ACCC's decision.

The asset manager's reduction in Sigma shares has been ongoing, starting back in April when it sold approximately 4% of its holdings.

HMC initially bought into Sigma at around 70 cents per share in 2022, according to The Australian, making its recent sales an exit at a solid profit.

The financial services company isn't exiting Sigma completely, however. It is just reducing its holdings.

Still, brokers are cautious about what's next. According to CommSec, consensus rates the stock a 'moderate' sell.

This comprises three sell ratings, four holds, and one broker still advising to buy Sigma shares.

Where is HMC Capital now investing?

Where or how HMC will use the funds generated from the sell-downs isn't clear. But elsewhere, the company is channelling its resources into the digital infrastructure space.

In a separate update, the company announced it acquired the iSeek data centre platform in Australia for $400 million. It marks the foundation of its planned DigiCo digital infrastructure platform.

The acquisition, alongside others, could form the basis of a future ASX-listed property trust:

These acquisitions will seed an ASX-listed DigiCo Infrastructure REIT (DigiCo REIT)
2 with [over $4 billion] of [assets under management] AUM…

… Once it is established, it is proposed that DigiCo REIT will be a stapled entity consisting of a company and a registered managed investment scheme. Shares in the company will be stapled to units in the managed investment scheme on a one for one basis to form stapled securities.

Foolish takeaway

Sigma shares are in the limelight after the ACCC approved its merger with Chemist Warehouse this month.

Where to from here is a matter of economic debate, but also the fundamentals of both companies.

Sigma shares are up more than 267% in the past year.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »